Answers are grounded in this paper and cite their sources.
Systematic review reveals distinct efficacy and safety profiles for second-line Janus kinase inhibitors in myelofibrosis, suggesting treatment should be tailored to patient phenotypes.
Ruxolitinib remains first-line standard of care for symptomatic myelofibrosis, but resistance/intolerance develops in most patients. Three Janus kinase inhibitors (JAKis) have entered the post-ruxolitinib space via distinct pivotal trials. We systematically searched prospective trials evaluating JAKi in refractory adults with myelofibrosis. Efficacy was assessed across phase 3 trials, with safety integrating phase 2 and real-world data. Pooled ≥35% spleen volume reduction at week 24 was 32.7% (95% confidence intervals 27.3-38.6) for fedratinib, 15.8% (11.7-21.0) for momelotinib and 21.6% (13.8-32.3) for pacritinib 200 mg bis in die; pooled ≥50% Total Symptom Score reduction rates were 32.8% (27.4-38.7), 25.3% (20.2-31.3) and 32.4% (22.9-43.7) respectively. Across safety datasets (n = 1004 trial; n = 790 real-world), fedratinib showed the highest grade ≥3 anaemia (34.3%) and any-grade diarrhoea (56.6%), whereas momelotinib the lowest (8.0%). Pacritinib carried the greatest risk of grade ≥3 bleeding (11.2%). Discontinuation due to adverse events was comparable across agents (~16%-17%). Real-world evidence from five momelotinib cohorts (n = 580) identified nephrotoxicity (glomerular filtration rate decline 17%-29%) and peripheral neuropathy (4%-20%) as monitoring targets. Despite limitations from differing study designs, each post-ruxolitinib JAKi shows a distinct efficacy/safety fingerprint mapping onto a phenotype, guiding second-line choice by clinical factors and prior adverse events.
No takes yet. Share an insight, caveat, or question.
Duminuco et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: